Pantothenic Acid for Health & Longevity

Evidence Review created on 04/26/2026 using AI4L / Opus 4.7

Also known as: Vitamin B5, Pantothenate, Calcium Pantothenate, D-Pantothenic Acid, Pantothenol, Dexpanthenol, Pantethine

Motivation

Pantothenic acid (vitamin B5) is an essential water-soluble vitamin that the body uses to build a key cofactor central to cellular energy production. The Greek root “pantos” – meaning “everywhere” – reflects its near-ubiquitous presence in foods, which is why overt deficiency is exceedingly rare outside severe malnutrition.

Despite this widespread availability, two clinical applications have driven interest in supplemental doses well above the recommended intake: pantethine, a derivative of pantothenic acid, has been studied for the modest lowering of cholesterol and triglycerides in adults with dyslipidemia, and high-dose oral pantothenic acid has been investigated as a potential intervention for mild-to-moderate facial acne. Decades of widespread use of the topical alcohol form (dexpanthenol) for skin and wound care provide a separate, well-established line of evidence in dermatology.

This review examines the evidence for and against pantothenic acid (and pantethine), focusing primarily on cardiovascular and dermatologic applications, the safety profile across the dosing range, and how supplementation fits into a broader health and longevity strategy.

Benefits - Risks - Protocol - Conclusion

Grokipedia

Pantothenic Acid

Comprehensive entry covering pantothenic acid as vitamin B5, its role as the obligatory precursor of coenzyme A, biochemical functions in fatty acid, carbohydrate, and protein metabolism, dietary sources, and recommended intakes across human and companion-animal nutrition.

Examine

No dedicated Examine.com page on pantothenic acid was located.

ConsumerLab

No dedicated ConsumerLab page on pantothenic acid was located; coverage exists only within the broader B Vitamin Supplements Review.

Systematic Reviews

A selection of systematic reviews and meta-analyses evaluating pantothenic acid’s clinical efficacy and safety across its most studied therapeutic domains.

ESPEN micronutrient guideline - Berger et al., 2022

European Society for Clinical Nutrition and Metabolism evidence-based guideline reviewing 13 vitamins (including pantothenic acid) and 15 trace elements, summarizing daily requirements, deficiency biomarkers, and clinical scenarios in which supplementation is justified, including the role of pantothenic acid in coenzyme A synthesis and energy metabolism.
Diagnosis and Treatment of Pantothenate Kinase-Associated Neurodegeneration (PKAN): A Systematic Review - Pohane et al., 2023

Systematic review of pantothenate kinase-associated neurodegeneration, a rare inherited disorder of CoA biosynthesis, summarizing diagnostic criteria, the rationale for high-dose pantothenate and pantethine therapy in patients with residual PANK2 (pantothenate kinase 2, the rate-limiting enzyme that initiates CoA biosynthesis from pantothenate) enzyme activity, and the limits of current pharmacological strategies.
Safety and efficacy of vitamin B in cancer treatments: A systematic review - Van de Roovaart et al., 2024

Systematic review of 25 trials covering vitamins B1, B2, B3, B5, B6, B9, and B12 in oncology, finding mixed effects on cancer risk and chemotherapy adverse events, and concluding that the safety and efficacy of B-vitamin supplementation in cancer is highly context-dependent and requires larger RCTs (randomized controlled trials, the gold-standard study design that randomly assigns participants to intervention or control to test causation).
Demand for Water-Soluble Vitamins in a Group of Patients with CKD versus Interventions and Supplementation – A Systematic Review - Kędzierska-Kapuza et al., 2023

Systematic review summarizing water-soluble vitamin requirements (including pantothenic acid) in chronic kidney disease (CKD, a condition of progressively reduced kidney function) and on dialysis, where altered metabolism and dialysate losses can shift requirements; relevant for assessing pantothenic acid status in older adults with renal impairment.

Mechanism of Action

Pantothenic acid is the obligate precursor of two essential coenzymes that participate in hundreds of enzymatic reactions across nearly every metabolic pathway:

Coenzyme A (CoA) synthesis: Pantothenic acid enters cells via the sodium-dependent multivitamin transporter (SLC5A6) and is sequentially converted to CoA by five enzymes, with pantothenate kinase 2 (PANK2, the rate-limiting enzyme of CoA biosynthesis) catalyzing the first step. CoA is the universal acyl-group carrier required for the citric acid cycle (also called the tricarboxylic acid (TCA) cycle, the metabolic hub by which carbohydrates, fats, and proteins generate ATP (adenosine triphosphate, the cell’s energy currency)), pyruvate dehydrogenase, alpha-ketoglutarate dehydrogenase, fatty acid beta-oxidation, ketone body synthesis, and acetylcholine synthesis. Loss of CoA capacity impairs cellular energy production globally
Acyl carrier protein (ACP): A 4’-phosphopantetheine prosthetic group derived from CoA is covalently attached to ACP, the scaffold protein on which fatty acid biosynthesis occurs. ACP is also required for the assembly of mitochondrial respiratory complex I, lipoic acid biosynthesis, and the mevalonate pathway, linking pantothenic acid status to cholesterol and isoprenoid synthesis as well as to oxidative phosphorylation
Lipid metabolism via pantethine: Pantethine – two pantothenic acid molecules joined by a disulfide bridge to two cysteamine moieties – is hydrolyzed in vivo to release cysteamine, which inhibits acetyl-CoA carboxylase and HMG-CoA reductase (3-hydroxy-3-methylglutaryl-CoA reductase, the rate-limiting enzyme of cholesterol biosynthesis and the target of statin drugs) activity and downregulates SREBP2 (sterol regulatory element-binding protein 2, a transcription factor controlling cholesterol synthesis). This is the proposed mechanism for pantethine’s modest cholesterol- and triglyceride-lowering effects, distinct from the metabolic role of pantothenic acid as a CoA precursor
Steroid and neurotransmitter synthesis: CoA is required for the production of steroid hormones (including cortisol and the sex steroids) from cholesterol and for the synthesis of acetylcholine via choline acetyltransferase. Reduced CoA availability has been linked experimentally to impaired adrenal function and reduced acetylcholine synthesis in animal models of pantothenic acid deficiency
Tumor metabolism (MYC-driven cancers): Recent mechanistic work shows that the oncogene MYC (a transcription factor that drives cell proliferation and is amplified or overexpressed in many aggressive cancers) upregulates SLC5A6 in tumors, increasing pantothenic acid uptake to fuel CoA-dependent biosynthetic pathways. Dietary restriction of pantothenic acid slows MYC-driven mammary tumor growth in mice, identifying B5 as a context-dependent metabolic substrate that can be co-opted by certain cancers
Immune function: Pantothenic acid and CoA promote the differentiation of CD8+ cytotoxic T cells into IL-22 (interleukin-22, a signaling protein that supports tissue repair and antimicrobial defense)-producing Tc22 cells through enhanced mitochondrial metabolism. In mice and a small cohort of melanoma patients, plasma B5 levels correlate with response to PD-1 (programmed cell death protein 1, an immune checkpoint targeted by cancer immunotherapy) immunotherapy, suggesting a context-specific immunostimulatory role
Topical mechanism (dexpanthenol): Dexpanthenol, the alcohol analog of pantothenic acid, is rapidly oxidized to pantothenic acid in skin and acts as a humectant, stimulates fibroblast proliferation, and reduces inflammation, providing a mechanistic basis for its topical use in wound and barrier-disorder care
Pharmacological properties: Calcium pantothenate is rapidly absorbed orally (peak plasma at approximately 1 hour) with a long terminal half-life (reported up to ~225 hours in pharmacokinetic studies, reflecting tissue retention as long-lived intracellular CoA pools); pantethine has a reported half-life of approximately 28 hours. Selectivity is non-specific — pantothenic acid acts as a substrate for the broadly distributed SLC5A6 transporter (also shared with biotin and lipoate) and the ubiquitous CoA biosynthesis enzymes, with no tissue-selective receptor. Tissue distribution is wide, with highest pools in liver, kidney, heart, and adrenal cortex. Metabolism: pantothenate is incorporated into CoA via the five-enzyme pathway initiated by PANK2; excess unmodified pantothenic acid is rapidly cleared in urine, and there is no significant cytochrome P450 (CYP) involvement

Historical Context & Evolution

Pantothenic acid’s discovery and clinical use span almost a century of nutritional and pharmaceutical research:

1931-1933: Roger Williams identified an unknown growth factor for yeast in liver extracts and named it pantothenic acid (Greek “pantothen,” meaning “from everywhere”) because of its widespread distribution in tissues. Williams isolated and synthesized the pure compound by the late 1930s
1939-1947: Williams’ team established the chemical structure and synthesis of pantothenic acid; Lipmann and colleagues identified coenzyme A as the active form mediating acetyl-group transfer in the citric acid cycle, work for which Lipmann shared the 1953 Nobel Prize in Physiology or Medicine
1950s-1970s: Pantothenic acid was added to multivitamin formulations and used clinically to manage symptoms attributed to “stress” and adrenal fatigue, although these indications were never validated in controlled trials. During the same period, dexpanthenol (the alcohol form) was introduced into topical preparations for wound and skin-barrier care, where it has remained in widespread use for over 70 years
1960s-1990s: Italian and Japanese investigators reported that pantethine, a disulfide derivative of pantothenic acid, lowered total and LDL (low-density lipoprotein, the primary cholesterol-carrying particle most strongly linked to cardiovascular risk) cholesterol and triglycerides in patients with dyslipidemia. Multiple small open-label studies and short-term controlled trials supported this effect, mostly in higher-risk populations
1995: Vaxman and colleagues published a double-blind RCT showing that combined oral pantothenic acid and ascorbic acid improved a biomarker of skin wound healing (hydroxyproline content) in patients undergoing tattoo excision, supporting the long-standing clinical use of B5 for skin repair
2011-2014: Rumberger and Evans conducted modern, triple-blinded, placebo- and diet-controlled RCTs of pantethine in low- to moderate-cardiovascular-risk North American adults eligible for statin therapy, confirming an approximately 11% reduction in LDL cholesterol at 16 weeks. In parallel, Yang et al. published the first modern RCT of an oral pantothenic-acid-based supplement showing significant reductions in inflammatory acne lesions
2010s-2020s: Genetic discoveries linked pantothenate kinase 2 mutations to pantothenate kinase-associated neurodegeneration (PKAN), a rare disorder of CoA biosynthesis, motivating high-dose pantothenate and pantethine as repurposed therapies. Concurrently, basic research showed that age-related decline in CoA pools impairs intestinal stem cell function and that cerebral pantothenate deficiency is associated with reduced TCA-cycle enzyme activity in Alzheimer’s disease
2022-2025: Translational immuno-oncology studies demonstrated that pantothenic acid supports anti-tumor T cell responses and enhances PD-1 immunotherapy in melanoma models. The PANTHEON-IO Phase 1 trial (NCT06377111) is currently testing 2,000 mg daily calcium pantothenate alongside checkpoint inhibitors in metastatic melanoma. Mechanistic work has also identified MYC-driven tumors as preferentially dependent on pantothenic acid uptake, raising the prospect that very high B5 intake may be context-dependent in cancer biology

Expected Benefits

High 🟩 🟩 🟩

Topical Wound Healing & Skin Barrier Support (Dexpanthenol)

Topical dexpanthenol (the alcohol form of pantothenic acid) has 70+ years of clinical use and a robust evidence base for supporting wound healing across the inflammation, proliferation, and remodeling phases. Multiple controlled studies and dermatology reviews report improved wound closure, reduced transepidermal water loss, reduced erythema and pruritus in barrier disorders (atopic dermatitis, irritant dermatitis, diaper dermatitis), and faster recovery from minor cuts, abrasions, and post-procedural skin. The Baron et al. 2020 review in Dermatology summarized the evidence supporting dexpanthenol-containing formulations as first-line over-the-counter wound care, and the 2017 70th-anniversary review by Proksch et al. in the Journal of Dermatological Treatment compiled the cumulative clinical and mechanistic evidence. The benefit applies to topical use specifically; benefits from oral supplementation for skin healing are less well established.

Magnitude: Significant improvements in wound closure rates, hydration, and reduction in erythema/pruritus across multiple controlled trials; clinically meaningful effect sizes for minor wounds and barrier disorders, recognized by dermatology consensus.

Medium 🟩 🟩

Lipid Lowering (Pantethine, Not Standard Pantothenic Acid)

Pantethine (typically 600-900 mg/day) modestly lowers total cholesterol, LDL cholesterol, triglycerides, and apolipoprotein B in adults with dyslipidemia. The Rumberger et al. 2011 (n=120) and Evans et al. 2014 (n=32) triple-blinded, placebo- and diet-controlled RCTs in low- to moderate-cardiovascular-risk North Americans eligible for statin therapy showed significant reductions in total and LDL cholesterol versus placebo over 16 weeks, with approximately 11% LDL-C reduction from baseline in the 2014 study and 4-6 mg/dL absolute reductions in the 2011 study (over and above a therapeutic lifestyle change diet); earlier Italian and Japanese trials in higher-risk populations reported larger effects (10-15% LDL reductions, 25-30% triglyceride reductions). The benefit is specific to pantethine, not standard pantothenic acid; the mechanism appears to involve cysteamine-mediated inhibition of cholesterol and fatty acid synthesis, with overall magnitude consistently modest and well below statin efficacy. The studies have been industry-funded (Kyowa Hakko/Daiichi Fine Chemical, manufacturers of branded pantethine), a conflict of interest that should be considered when weighing the data.

Magnitude: Approximately 4-11% reduction in LDL-C over 16 weeks at 600-900 mg/day pantethine in low- to moderate-risk North American adults; up to 10-15% reductions in LDL and 20-30% reductions in triglycerides reported in older European/Japanese trials in higher-risk populations.

Mild to Moderate Acne Reduction (High-Dose Oral Pantothenic Acid)

A 12-week double-blind, placebo-controlled RCT (Yang et al. 2014, n=48 enrolled, 41 evaluable) of an oral pantothenic-acid-based dietary supplement in adults with mild to moderate facial acne reported significant reductions in total and inflammatory lesion counts and improvements in DLQI (Dermatology Life Quality Index, a validated patient-reported outcome measure of skin disease impact) scores versus placebo at 12 weeks (p=0.0197 for total lesion count). The supplement was safe and well tolerated. The proposed mechanism is enhanced fatty-acid metabolism via increased CoA availability, reducing sebaceous lipid accumulation. Evidence is rated Medium because it is supported by a single modern RCT of modest size in an industry-tied product context, with prior support coming from open-label and case-series literature; replication in independent trials has not yet been published.

Magnitude: Statistically significant reduction in total lesion count and inflammatory lesion count at 12 weeks versus placebo; effect size of similar magnitude to over-the-counter topical agents in the same severity range.

Low 🟩

Oral Pantothenic Acid for Adjunct Wound Healing

A 1995 double-blind RCT (Vaxman et al.) found that 200 mg/day pantothenic acid combined with 1 g/day vitamin C improved hydroxyproline content (a collagen biomarker) in healing scar tissue after tattoo excision, suggesting an adjunct role for oral B5 in skin repair. Animal studies in rabbits (Aprahamian et al. 1985) and in vitro fibroblast studies (Lacroix et al. 1988) support a role for pantothenic acid in proliferation and connective tissue synthesis. The evidence is older, limited to small trials, and confounded by co-administration with vitamin C; clinically meaningful improvements in wound healing rates with oral pantothenic acid alone in well-nourished adults have not been clearly demonstrated.

Magnitude: Improvement in hydroxyproline biomarker of collagen synthesis at 200 mg/day combined with 1 g/day vitamin C; clinical wound-closure benefit not robustly quantified.

Lipid Lowering with Standard Pantothenic Acid (Older Trials) ⚠️ Conflicted

A small body of older European and Japanese literature (1980s-1990s) reported modest cholesterol- and triglyceride-lowering effects with standard pantothenic acid at high doses (300-1,200 mg/day). The signal is weaker and less consistent than for pantethine and is largely superseded by the modern pantethine RCTs. The evidence is inconsistent: some trials reported small reductions in total cholesterol and triglycerides, while others (especially in healthy individuals or at lower doses) found no effect. The bulk of the modern evidence supports pantethine, not the parent vitamin, as the lipid-active form, and most major lipid guidelines do not include pantothenic acid as a recognized lipid-lowering intervention.

Magnitude: Inconsistent; small trials suggest modest reductions in total cholesterol and triglycerides at 300-1,200 mg/day, but pantethine is the better-supported derivative.

Speculative 🟨

Cognitive Support in Alzheimer’s Disease

A 2022 study (Sang et al., Frontiers in Aging Neuroscience) reported that CoA-dependent TCA cycle enzymes are decreased in Alzheimer’s disease brains, consistent with cerebral pantothenate deficiency, and a 2023 mouse study (Chen et al., Molecular Nutrition & Food Research) reported that oral pantethine improved spatial learning, reduced amyloid-beta production, and modulated gut microbiota in a triple-transgenic Alzheimer’s mouse model. The hypothesis that pantothenate or pantethine supplementation could slow cognitive decline in humans is mechanistically plausible but has not been tested in any controlled human trial, and effects on the human brain pantothenate pool with oral supplementation are uncertain.

Cancer Immunotherapy Enhancement ⚠️ Conflicted

A 2022 Cell Metabolism study (followed by editorial commentary by Bourgin, Kepp, and Kroemer) found that vitamin B5/CoA promotes IL-22-producing Tc22 cells and that plasma B5 levels correlate with PD-1 immunotherapy response in a small melanoma cohort. The PANTHEON-IO Phase 1 trial is currently testing 2,000 mg/day calcium pantothenate alongside nivolumab plus ipilimumab in metastatic melanoma. The same body of work has identified MYC-driven tumors as preferentially dependent on pantothenic acid uptake, raising a context-dependent concern that very high B5 intake could fuel certain cancers. Human evidence is limited to a small cohort and one ongoing Phase 1 trial.

Pantothenate Kinase-Associated Neurodegeneration (PKAN) Augmentation

In PKAN, partial-loss-of-function PANK2 mutations leave residual enzyme activity that may be exploitable by very high pantothenate or pantethine intake. A 2024 pilot study (Pereira et al., Orphanet J Rare Dis) reported improvements or stabilization in three PKAN patients receiving multitarget supplementation including pantothenate and pantethine alongside standard neurological care. PKAN is a rare orphan disease and these results are not generalizable to common longevity goals, but they illustrate the relevance of the CoA pathway to neurological function.

Stress, Adrenal, and Cortisol Support

Animal studies from the 1980s reported that pantothenic acid deficiency reduces adrenal cortex cortisol output and that supplementation can normalize stress responses. Clinical claims that pantothenic acid supports adrenal function or “adrenal fatigue” are widely repeated in popular health literature but are not supported by controlled human trials. The biological basis (CoA is required for steroidogenesis from cholesterol) is mechanistic and indirect.

Healthy Aging via CoA Pool Maintenance

A 2025 PLOS Genetics study (Liu et al.) reported that age-associated decline in CoA in Drosophila intestinal stem cells contributes to dysfunction via disturbed iron homeostasis, and that pantothenate supplementation rescues some age-related phenotypes. Whether oral pantothenate raises tissue CoA levels meaningfully in healthy adults, and whether such an effect translates to longevity outcomes, has not been demonstrated.

Benefit-Modifying Factors

Baseline pantothenic acid status: Subclinical deficiency is rare in well-nourished adults but more likely in those with severe malnutrition, alcohol use disorder, malabsorptive conditions (Crohn’s disease, celiac disease, post-bariatric surgery), or in older adults with reduced dietary intake. Individuals with low baseline status are most likely to derive measurable benefit from supplementation across all outcomes
Genetic polymorphisms: Heterozygous PANK2 carriers (parents and siblings of PKAN patients) may have reduced CoA biosynthesis capacity and could theoretically respond to higher pantothenic acid intake, though this has not been clinically validated. The SLC5A6 multivitamin transporter has known polymorphisms affecting B5 uptake but their impact on supplement response is not established
Sex-based differences: No established sex-based differences in benefit magnitude. Women have a slightly higher Adequate Intake (AI) during pregnancy (6 mg/day) and lactation (7 mg/day) than the general adult AI of 5 mg/day. Acne trial populations are typically mixed-sex; lipid-lowering trials with pantethine have included both men and women without reported sex-based differences in response
Age-related considerations: Older adults may have somewhat reduced gastrointestinal absorption and increased metabolic demands consistent with the broader age-related decline in CoA pools observed in preclinical aging models. The 2022 Frontiers in Aging Neuroscience study by Sang et al. reported decreased CoA-dependent TCA-cycle enzymes in Alzheimer’s brains, consistent with cerebral pantothenate deficiency. There is no established age-specific dosing recommendation in the longevity literature
Pre-existing health conditions: Individuals with dyslipidemia and acne are the best-characterized responder groups for supplemental pantethine and pantothenic acid, respectively. Patients with PKAN have a defined molecular target. Patients with malabsorption or on long-term parenteral nutrition may have higher requirements

Potential Risks & Side Effects

High 🟥 🟥 🟥

No high-evidence risks have been identified for pantothenic acid within the studied dose range (up to 10 g/day in some studies). The U.S. Food and Nutrition Board has not established a Tolerable Upper Intake Level (UL) because no adverse effects have been reliably associated with high intake from food or supplements in healthy adults. Limited absorption at higher doses (saturable SLC5A6 transport) and rapid renal excretion provide a natural ceiling on tissue accumulation. RCTs of pantethine at 600-900 mg/day for 16 weeks and oral pantothenic-acid-based supplements at therapeutic doses for acne for 12 weeks have reported good safety profiles with no serious adverse events versus placebo.

Medium 🟥 🟥

Mild Gastrointestinal Effects

Diarrhea, nausea, and gastrointestinal discomfort have been reported, particularly at very high doses (greater than 1-2 g/day) and with pantethine. The NIH Office of Dietary Supplements notes that doses of 10 g/day and higher have been associated with mild diarrhea in some individuals. In modern RCTs of pantethine 600-900 mg/day, GI adverse events were not significantly different from placebo. The effect is generally dose-dependent, mild, and reversible.

Magnitude: Uncommon at typical therapeutic doses (200-900 mg/day); more frequent and dose-related at multi-gram doses; not significantly different from placebo in 16-week pantethine trials at 900 mg/day.

Low 🟥

Theoretical Tumor-Fueling at Very High Doses in MYC-Driven Cancers ⚠️ Conflicted

A 2023 Nature Metabolism study (Kreuzaler et al.) demonstrated that MYC-driven mammary tumors upregulate the pantothenic acid transporter SLC5A6 to fuel CoA-dependent biosynthesis, and that dietary pantothenic acid restriction slowed tumor growth in mice. Conversely, a 2022 Cell Metabolism study and the ongoing PANTHEON-IO Phase 1 trial (NCT06377111) frame pantothenic acid supplementation as a potential immunotherapy adjuvant in melanoma. The two findings are not necessarily incompatible – they describe different biological contexts (tumor-cell-intrinsic metabolism vs. immune-cell metabolism) – but they highlight that very high B5 intake (multi-gram daily) may be context-dependent in cancer biology and is not universally beneficial. No human evidence has linked dietary or supplemental B5 intake to cancer incidence or progression in general populations.

Magnitude: Preclinical signal in MYC-driven mouse mammary tumors at high pantothenate intake; no demonstrated effect in human cancer epidemiology.

Drug Interaction with Levodopa (Theoretical)

Older case-series data suggest that high-dose pantothenic acid may reduce the efficacy of levodopa in Parkinson’s disease, possibly by increasing peripheral conversion of levodopa to dopamine. The effect is not seen when levodopa is co-administered with carbidopa, the standard modern formulation. This concern is largely historical but is still mentioned in some pharmacology references.

Magnitude: Historical concern with levodopa monotherapy; minimal relevance to modern carbidopa/levodopa combinations.

Speculative 🟨

Sulfurous Body Odor at Very High Pantethine Doses

Anecdotal reports describe a mild sulfurous body or breath odor at very high pantethine doses, attributed to cysteamine metabolism. This is not commonly reported in controlled trials and resolves with dose reduction.

B Vitamin Imbalance with Prolonged Single-Nutrient Supplementation

Prolonged high-dose supplementation with any single B vitamin could theoretically create a relative imbalance in other B vitamins, given the metabolic interdependencies among them. This concern is primarily theoretical and has not been documented for pantothenic acid specifically.

Risk-Modifying Factors

Genetic polymorphisms: No genetic polymorphisms have been identified that increase the risk of adverse effects from pantothenic acid supplementation. PANK2 mutations increase the rationale for high-dose therapy in PKAN but do not modify the side-effect profile
Baseline biomarker levels: Individuals with severe renal impairment theoretically have reduced excretory capacity for water-soluble vitamins, but no clinically significant accumulation or toxicity from pantothenic acid has been documented even in CKD or dialysis populations. The 2023 systematic review by Kędzierska-Kapuza et al. found that CKD patients often have altered, sometimes reduced, water-soluble vitamin status rather than excess
Sex-based differences: No sex-based differences in pantothenic acid side effects have been identified in clinical trials or safety databases
Age-related considerations: No age-related increases in adverse effects have been documented. Pantothenic acid is considered safe across all age groups, including infants, children, the elderly, and during pregnancy and lactation
Pre-existing health conditions: Individuals with active cancer, particularly MYC-driven malignancies, should discuss high-dose B5 supplementation with their oncologist given the preclinical signal that very high pantothenate availability may support tumor metabolism in some contexts. Individuals with inflammatory bowel disease may be more sensitive to high-dose GI effects

Key Interactions & Contraindications

Levodopa interaction (historical): High-dose pantothenic acid may theoretically reduce the central nervous system efficacy of levodopa monotherapy by promoting peripheral decarboxylation; severity: caution; clinical consequence: reduced symptom control in Parkinson’s disease. Mitigating action: this concern is largely obviated by modern carbidopa/levodopa combinations, which inhibit peripheral decarboxylation; nonetheless, individuals on levodopa-based therapy should disclose B5 supplementation to their neurologist
Prescription drug interactions: No major prescription drug interactions have been established for pantothenic acid at standard doses. Tetracycline antibiotics (e.g., doxycycline, minocycline) absorption may be reduced when taken with multivitamins containing pantothenic acid plus minerals; severity: caution; clinical consequence: reduced antibiotic efficacy. Mitigating action: separate doses by 2 hours
Cholinesterase inhibitor interaction: Pantothenic acid can theoretically enhance the effects of cholinesterase inhibitors (drugs that block the enzyme that breaks down acetylcholine, thereby raising acetylcholine levels; e.g., donepezil, pyridostigmine) by increasing the availability of an acetylcholine precursor; severity: caution; clinical consequence: increased cholinergic side effects (nausea, diarrhea, increased salivation). Mitigating action: dose with awareness; not a contraindication
Over-the-counter medication interactions: No clinically significant interactions documented with common OTC medications (NSAIDs (non-steroidal anti-inflammatory drugs; e.g., ibuprofen, naproxen), acetaminophen, antihistamines (e.g., diphenhydramine, loratadine), PPIs (proton pump inhibitors; e.g., omeprazole, esomeprazole)). Long-term PPI use may modestly impair B5 absorption alongside other B vitamins
Supplement interactions: Pantothenic acid is compatible with all common supplements and is routinely included in B-complex and multivitamin formulations. Biotin shares the SLC5A6 transporter; very high doses of one may modestly compete with absorption of the other but no clinically meaningful interaction has been documented
Additive lipid-lowering effects (pantethine): Pantethine combined with statins, ezetimibe, red yeast rice, or other lipid-lowering agents may have additive cholesterol-lowering effects; severity: monitor; clinical consequence: greater LDL reduction. Mitigating action: monitor LDL and AST/ALT (liver enzymes) per standard practice; no adverse interactions reported
Other intervention interactions: No major interactions with common non-pharmacologic interventions (intermittent fasting, ketogenic diet, exercise) are documented. The active form of B5 is needed for fatty acid oxidation and energy metabolism, so adequate status supports rather than conflicts with these interventions
Populations who should avoid this intervention:
- Individuals with active MYC-driven cancers (e.g., MYC-amplified breast cancer, Burkitt lymphoma, MYC-amplified neuroblastoma) should avoid supplemental B5 intake exceeding 1,000 mg/day without oncology consultation, given preclinical signals at multi-gram pantothenate exposure
- Individuals receiving levodopa monotherapy without a peripheral decarboxylase inhibitor (carbidopa or benserazide) — rare in modern practice — should avoid supplemental B5 above 100 mg/day
- Individuals with documented allergy or hypersensitivity to a specific pantothenic acid formulation (any prior Type I hypersensitivity reaction such as urticaria, angioedema, or anaphylaxis to calcium pantothenate, dexpanthenol, or pantethine)
- Individuals with severe inflammatory bowel disease (active Crohn’s disease or ulcerative colitis flares) should limit pantethine doses to less than 600 mg/day to reduce GI side effect risk

Risk Mitigation Strategies

Stay within studied dose ranges: For acne, 2-2.5 g/day of an oral pantothenic-acid-based regimen has been studied for 12 weeks; for lipid lowering, 600-900 mg/day pantethine for 16 weeks has been studied; for general nutritional support, 5-25 mg/day is more than sufficient. Doses above 1-2 g/day should be reserved for specific indications and not used for general “stress support” or generic energy claims
Take with food: Taking pantothenic acid or pantethine with a meal reduces the likelihood of mild gastrointestinal discomfort and supports steady absorption via the intestinal SLC5A6 transporter
Disclose to oncologists: Individuals undergoing or considering immunotherapy or chemotherapy should disclose pantothenic acid supplementation to their oncology team, given emerging context-dependent effects on tumor and immune-cell metabolism
Monitor lipid panel when using pantethine for cholesterol management: Baseline and 8-16 week follow-up lipid panels (total cholesterol, LDL-C, HDL-C (high-density lipoprotein cholesterol, often called “good” cholesterol due to its inverse association with cardiovascular risk), triglycerides) provide objective evidence of efficacy at the individual level; expected reductions are modest (4-11% LDL)
Use B-complex for general support, single-nutrient for indications: For general nutritional optimization, pantothenic acid as part of a balanced B-complex supplement avoids the small theoretical risk of single-nutrient imbalance. Single-nutrient high-dose B5 should be reserved for specific indications (lipid lowering with pantethine, acne) for finite durations
Discontinue if persistent gastrointestinal symptoms occur: If diarrhea, nausea, or abdominal discomfort persists for more than a week at multi-gram doses, reduce the dose by 50% or discontinue; symptoms typically resolve within days

Therapeutic Protocol

The optimal pantothenic acid protocol varies substantially with the indication. There is no single standard “longevity dose” and no expert consensus that high-dose pantothenic acid supplementation extends healthspan in well-nourished adults.

General nutritional support dose: The U.S. Adequate Intake is 5 mg/day for adults (6 mg/day in pregnancy, 7 mg/day during lactation). 5-50 mg/day – the dose range typically present in B-complex and multivitamin supplements – provides a comfortable margin above the AI and ensures cofactor availability. Most healthy adults eating a varied diet meet or exceed the AI from food alone
Lipid-lowering protocol (pantethine): 600 mg/day for 1-8 weeks, then 900 mg/day from weeks 9-16, as used in the Rumberger and Evans trials. Some practitioners and prior trials use 900 mg/day in three divided doses (300 mg three times daily). Continuous use is reasonable for as long as the lipid benefit is desired; effects are modest and require continuation
Acne protocol (oral pantothenic acid): The Yang et al. 2014 RCT used a proprietary pantothenic-acid-based supplement at the manufacturer’s recommended dose for 12 weeks. Other case-series and clinical practice have used 2.5-10 g/day of calcium pantothenate in divided doses (typically 4 doses per day) for 12 weeks or longer; benefits typically appear by week 4-8 and stabilize by week 12. Lower doses (1-2 g/day) may be sufficient and better tolerated
Topical (dexpanthenol) protocol: 5% dexpanthenol creams, ointments, or sprays applied 1-3 times daily to affected skin for minor wounds, irritant or atopic dermatitis, post-procedural skin, or barrier disorders. Topical use is well-tolerated and can be continued for as long as needed; many over-the-counter products combine dexpanthenol with other emollients
PKAN augmentation: Specialist-supervised regimens combine high-dose pantothenate (typically 1,500-3,000 mg/day) and pantethine alongside other targeted nutrients (vitamin E, omega-3); not relevant to general health and longevity use
Best time of day: No specific time-of-day effects have been demonstrated. B5 can be taken with any meal. For lipid lowering, dosing with the largest meal of the day may align with peak postprandial cholesterol synthesis. There is no evidence that B5 disrupts sleep
Half-life considerations: Calcium pantothenate is rapidly absorbed (peak plasma at approximately 1 hour) with a long terminal half-life (reported up to ~225 hours in pharmacokinetic studies, reflecting tissue retention). Pantethine has a reported half-life of approximately 28 hours with body stores estimated at 25 mg/kg and plasma elevations persisting for months after a treatment course. Functional CoA effects persist beyond plasma half-lives because pantothenate is incorporated into long-lived intracellular CoA pools
Single dose vs. split doses: At low doses (5-50 mg/day), once-daily dosing is sufficient. At lipid-lowering pantethine doses (600-900 mg/day), splitting into 2-3 doses per day may improve tolerability and overlaps better with meals. At acne doses (multi-gram), 4 divided doses per day are typical
Genetic polymorphisms: No common pharmacogenetic variants meaningfully change protocol selection in the general population. PANK2 carriers and PKAN patients are managed by neurology specialists with individualized regimens
Sex-based differences: No sex-specific dose adjustments. AI is slightly higher in pregnancy and lactation
Age-related considerations: Older adults with low dietary intake or malabsorption may benefit from ensuring adequate B5 status via a B-complex; therapeutic doses for lipid lowering or acne use the same regimens as younger adults
Baseline biomarker levels: Whole-blood pantothenic acid (low) or 24-hour urinary pantothenic acid (less than 1 mg/day suggests inadequate intake) can document deficiency but are rarely needed in clinical practice. For lipid-lowering use, baseline and follow-up lipid panels provide the relevant outcome
Pre-existing health conditions: Patients with malabsorptive conditions or on long-term parenteral nutrition may need higher than dietary doses to maintain status. Patients with active cancer should consult their oncologist before initiating high-dose therapy

Discontinuation & Cycling

Lifelong vs. short-term use: For general nutritional adequacy, pantothenic acid intake from diet and/or a B-complex is appropriate as a continuous, lifelong baseline. For pantethine lipid lowering, continuous use is rational while the benefit is desired; effects revert toward baseline within weeks of discontinuation. For oral pantothenic acid for acne, 12-week courses are typical and can be repeated or continued depending on individual response
Withdrawal effects: No withdrawal effects or rebound phenomena have been reported. Lipid parameters and acne lesion counts revert toward pre-supplementation values over weeks to months, but this represents return to baseline, not a rebound
Tapering: No tapering protocol is required for any pantothenic acid form or dose. Discontinuation can be abrupt without adverse effects
Cycling: No cycling protocol is biologically warranted. Tolerance has not been described. Some practitioners use 12-week treatment courses for acne with 4-week breaks to reassess need, but this is empirical rather than evidence-based
Indication-specific reassessment: For lipid lowering, reassess at 8-16 weeks; if no meaningful LDL reduction, discontinue. For acne, reassess at 12 weeks; if no meaningful improvement, transition to other proven therapies

Sourcing and Quality

Standard forms available: Pantothenic acid is most commonly sold as calcium pantothenate (the stable salt) or D-pantothenic acid for oral use, dexpanthenol (the alcohol form) for topical use, and pantethine (the disulfide-linked active form) for lipid-lowering applications. All forms are well-absorbed orally; most healthy individuals interconvert them efficiently
Pantothenic acid vs. pantethine: For lipid lowering, pantethine is the form supported by modern RCTs. For general nutritional support and acne, calcium pantothenate is sufficient. Pantethine is typically more expensive than calcium pantothenate
Third-party testing: Choose products independently tested for potency and purity. ConsumerLab includes pantothenic acid (B-5) in its B Vitamin Supplements Review and has flagged label-accuracy issues across the broader B-vitamin category. USP (United States Pharmacopeia), NSF International, and ConsumerLab verification marks provide additional quality assurance
Reputable brands: Thorne, Pure Encapsulations, NOW Foods, Solgar, Life Extension, and Jarrow Formulas offer standalone calcium pantothenate (typically 250-500 mg per capsule) and B-complex products that have generally passed independent testing. For pantethine, Pantesin (a Daiichi Fine Chemical/Kyowa Hakko branded ingredient used in many U.S. supplements) is the form used in the modern RCTs
Standalone vs. B-complex: For general nutritional support, a high-quality B-complex provides balanced B-vitamin coverage. For specific therapeutic doses (lipid lowering with pantethine, high-dose acne regimens), standalone formulations are necessary because B-complex products do not contain therapeutic doses
Storage: Pantothenic acid is moderately stable; store in a cool, dry place away from direct light and heat. Calcium pantothenate is hygroscopic and should be kept tightly sealed

Practical Considerations

Time to effect: For pantethine lipid lowering, modest LDL reductions emerge by week 4 and are typically established by week 8-16 of consistent dosing. For oral pantothenic acid for acne, lesion-count improvements typically appear by week 4-8 and stabilize by week 12. Topical dexpanthenol effects on skin barrier and minor wound healing appear within days. There are no immediate “felt” effects of pantothenic acid supplementation in healthy adults
Common pitfalls:
- Confusing pantethine with pantothenic acid: the lipid-lowering literature is specific to pantethine; standard pantothenic acid does not produce equivalent lipid effects
- Expecting “stress” or “adrenal fatigue” benefits: these claims are not supported by controlled human trials, despite widespread marketing
- Underdosing for therapeutic indications: B-complex doses (5-50 mg) are insufficient for the lipid-lowering and acne indications, which require gram-level dosing
- Not knowing whether food intake already meets the AI: most healthy adults eating a varied diet meet the 5 mg/day AI without supplementation; deficiency is rare
- Conflating topical and oral effects: dexpanthenol’s wound-healing and skin-barrier benefits apply to topical use; oral pantothenic acid does not reliably reproduce these effects in healthy skin
Regulatory status: Pantothenic acid (calcium pantothenate, pantethine, dexpanthenol) is classified as a dietary supplement in the United States, Canada, and the European Union, and is available without prescription. It is not subject to the FDA’s (Food and Drug Administration, the U.S. agency that regulates drugs, biologics, and supplements) pre-market drug approval process. Topical dexpanthenol is included in many over-the-counter drug products
Cost and accessibility: Pantothenic acid supplements are inexpensive and widely available. Calcium pantothenate (500 mg) typically costs $5-15 USD per month; pantethine (600 mg) typically $20-40 USD per month; topical dexpanthenol creams $5-15 USD per tube. Even therapeutic-dose acne regimens (multi-gram daily) typically cost less than $50 USD per month

Interaction with Foundational Habits

Sleep: No significant interactions between pantothenic acid and sleep have been established. B5 is neither sedating nor stimulating and can be taken at any time of day. The vitamin’s role in mitochondrial energy metabolism does not translate into perceptible alertness or sleep effects in healthy adults; direct evidence either way is lacking
Nutrition: Pantothenic acid is widely distributed in foods, with the richest sources including liver and other organ meats, egg yolk, sunflower seeds, mushrooms (especially shiitake), avocado, broccoli, sweet potato, dairy products, fish, chicken, and whole grains. The U.S. average intake (5-6 mg/day) generally meets the AI. Pantothenate is partially destroyed by food processing (heat, freezing, refining), so heavily processed diets may provide less than expected. No specific dietary restrictions apply to supplementation; taking with food is preferred for tolerability and absorption
Exercise: Pantothenic acid’s role in fatty-acid oxidation and CoA-dependent energy metabolism makes it theoretically relevant to exercise capacity, but human trials of B5 supplementation for exercise performance in well-nourished athletes have generally been negative. There is no evidence that B5 supplementation improves performance, recovery, or hypertrophy in adequately fed individuals; conversely, deficiency would impair energy metabolism. No specific timing constraints around workouts are required
Stress management: Despite widespread claims that pantothenic acid supports adrenal function, controlled human trials do not support a meaningful effect of B5 supplementation on cortisol output, perceived stress, or stress resilience in well-nourished adults. The biological rationale (CoA is required for steroidogenesis from cholesterol) is real but indirect; ensuring adequate B5 intake is reasonable but high-dose supplementation for “adrenal support” is not evidence-based

Monitoring Protocol & Defining Success

Baseline assessment depends on the indication. For general nutritional adequacy, no testing is required; for lipid lowering with pantethine and for high-dose acne regimens, the following provide useful reference points:

Lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides, apolipoprotein B if available) for pantethine users
Liver function tests (AST, ALT) at baseline and every 8-16 weeks for high-dose users (precautionary, not driven by documented hepatotoxicity)
Acne lesion count and Dermatology Life Quality Index (DLQI) for acne users
Diet history to establish current pantothenic acid intake (rarely needed in clinical practice)
Whole-blood pantothenic acid or 24-hour urinary pantothenic acid in suspected deficiency (specialized labs)

Ongoing monitoring should be aligned with the indication; for general nutritional support, no laboratory monitoring is needed. For pantethine lipid lowering, repeat the lipid panel at 8 weeks and 16 weeks; for high-dose acne therapy, reassess clinical response at 4 and 12 weeks.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
LDL cholesterol	< 100 mg/dL (<70 mg/dL high-risk)	Tracks pantethine lipid response	Conventional reference: <130 mg/dL desirable; fasting 9-12 hours preferred; baseline and 8-16 weeks
Triglycerides	< 100 mg/dL	Tracks lipid response (older trials)	Conventional reference: <150 mg/dL; fasting required; baseline and 8-16 weeks
Apolipoprotein B	< 90 mg/dL	More sensitive marker of atherogenic particles	Conventional reference: <100-130 mg/dL depending on risk; non-fasting acceptable; optional
AST/ALT	< 25 U/L (women), < 30 U/L (men)	Surveillance during high-dose use	Conventional reference: <33-40 U/L; non-fasting; baseline and every 8-16 weeks at multi-gram dosing
Acne lesion count (total, inflammatory)	Decreasing trend	Tracks acne response	Tracked clinically by patient/clinician; baseline, week 4, week 12

Qualitative markers to monitor:

Skin: lesion count, redness, scarring, oiliness (acne indication)
Wound healing: closure rate, redness, comfort (topical dexpanthenol)
Lipid-lowering tolerability: GI symptoms, body odor (very rare), general well-being
Energy and cognitive clarity (typically unchanged in well-nourished adults)
Bowel habits (in case of dose-related GI effects)

Emerging Research

Several ongoing trials and research directions may significantly expand pantothenic acid’s evidence base:

PANTHEON-IO Phase 1 trial: A Phase 1 single-cohort trial (NCT06377111) at Princess Margaret Cancer Centre is testing 2,000 mg/day calcium pantothenate added to nivolumab plus ipilimumab in 12 patients with metastatic or unresectable melanoma. The primary endpoint is plasma pantothenic acid increase at week 9, with secondary endpoints including overall response rate, immune-related colitis incidence, microbiome composition, and immune profiling – the first prospective human test of B5 as an immunotherapy adjuvant
MYC-driven cancer metabolism: Kreuzaler et al. (2023, Nature Metabolism) demonstrated that MYC-high tumor regions overexpress the SLC5A6 transporter and depend on pantothenic acid for CoA-fueled biosynthesis, with dietary B5 restriction slowing mouse mammary tumor growth. Future research is expected to clarify whether high-B5 intake matters in MYC-driven human cancers
Cerebral pantothenate and Alzheimer’s disease: Sang et al. (2022, Frontiers in Aging Neuroscience) reported that CoA-dependent TCA-cycle enzymes are decreased in Alzheimer’s disease brains, consistent with cerebral pantothenate deficiency. Whether oral pantothenate or pantethine raises brain pantothenate pools in humans, and whether this slows cognitive decline, remains untested in trials
CoA decline in aging stem cells: Liu et al. (2025, PLOS Genetics) showed that age-associated CoA decline in Drosophila intestinal stem cells contributes to dysfunction via disturbed iron homeostasis, with rescue by pantothenate. Translation to mammals and humans is the natural next step
PKAN augmentation strategies: Pereira et al. (2024, Orphanet J Rare Dis) reported a small pilot of multitarget supplementation (pantothenate, pantethine, omega-3, vitamin E) in three PKAN patients, showing biological and clinical signals. Larger, controlled PKAN trials are anticipated
Pantethine in Alzheimer’s mouse models: Chen et al. (2023, Molecular Nutrition & Food Research) showed pantethine improved cognition, reduced amyloid-beta production, and modulated gut microbiota in a 3xTg-AD mouse model – a hypothesis-generating preclinical signal that has not yet been tested in human Alzheimer’s trials
Vitamin B family in mitochondrial energy metabolism: Ongoing reviews (e.g., Depeint et al., 2006, Chem Biol Interact, foundational; updated 2020s) continue to refine the integrated role of pantothenic acid alongside other B vitamins in mitochondrial respiration, with implications for age-related metabolic decline

Conclusion

Pantothenic acid is a foundational water-soluble vitamin whose role as a precursor of coenzyme A places it at the center of energy metabolism, fatty acid synthesis, and steroid and neurotransmitter production. Because it is widely distributed in foods and overt deficiency is exceedingly rare in well-nourished adults, the clinically interesting questions concentrate on supplemental doses well above the recommended intake.

The strongest evidence for benefit lies in topical dexpanthenol for minor wounds and skin-barrier disorders, with decades of clinical use and broad dermatologic acceptance. The next-strongest evidence supports pantethine – the disulfide derivative – for modest lipid lowering in low- to moderate-risk adults eligible for statins; the effect is meaningful but well below statin efficacy, and most pivotal pantethine trials were sponsored by Kyowa Hakko/Daiichi Fine Chemical, the manufacturers of branded pantethine, a conflict of interest that should be considered when weighing the data. A single modern controlled trial supports oral high-dose pantothenic acid for mild-to-moderate facial acne, in a similarly industry-tied product context.

Beyond these specific applications, evidence for “adrenal support,” longevity effects, exercise enhancement, or generic stress benefits is mechanistic, indirect, or absent. Emerging preclinical and early-phase work in cancer immunotherapy, certain tumor types, neurodegeneration, and aging is intriguing but not yet ready to inform individual decisions. Pantothenic acid’s safety profile is excellent across the studied range, and its low cost and wide availability mean that, where an indication is well established, it remains an accessible option, while broader marketing claims remain unsupported by controlled human evidence.

Top - Benefits - Risks - Protocol

Pantothenic Acid for Health & Longevity

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

High 🟩 🟩 🟩

Topical Wound Healing & Skin Barrier Support (Dexpanthenol)

Medium 🟩 🟩

Lipid Lowering (Pantethine, Not Standard Pantothenic Acid)

Mild to Moderate Acne Reduction (High-Dose Oral Pantothenic Acid)

Low 🟩

Oral Pantothenic Acid for Adjunct Wound Healing

Lipid Lowering with Standard Pantothenic Acid (Older Trials) ⚠️ Conflicted

Speculative 🟨

Cognitive Support in Alzheimer’s Disease

Cancer Immunotherapy Enhancement ⚠️ Conflicted

Pantothenate Kinase-Associated Neurodegeneration (PKAN) Augmentation

Stress, Adrenal, and Cortisol Support

Healthy Aging via CoA Pool Maintenance

Benefit-Modifying Factors

Potential Risks & Side Effects

High 🟥 🟥 🟥

Medium 🟥 🟥

Mild Gastrointestinal Effects

Low 🟥

Theoretical Tumor-Fueling at Very High Doses in MYC-Driven Cancers ⚠️ Conflicted

Drug Interaction with Levodopa (Theoretical)

Speculative 🟨

Sulfurous Body Odor at Very High Pantethine Doses

B Vitamin Imbalance with Prolonged Single-Nutrient Supplementation

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion